|Day Low/High||85.46 / 86.86|
|52 Wk Low/High||62.55 / 101.28|
I'm watching the shares of Estee Lauder, Disney and Amazon.
AbbVie's weekly chart indicates its stock has room to run long term, but its daily chart suggests a rally in its shares is not imminent.
I think, ultimately, the big issue for many will be what happens in the United States if we hear about people who didn't go to China who have come down with the disease.
Nobody in AbbVie right now is in it for the past performance.
ABBV could bounce today but there remains the risk of a deeper correction.
Chinese President Xi Jinping, not a man given to exaggerate, has referred to the spread of this coronavirus in China as 'a grave situation.'
These companies all could be strong -- even if the 2019 nCoV fear spreads.
The Medical Technology Stock Letter's top pick rose 357% in 2019.
How to prepare your portfolio and be opportunistic in the face of this geopolitical instability.
As it smooths out the wrinkles from 2019, this pharmaceutical manufacturer should have a healthy year.
This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.
It seemed to happen overnight. People watched. People listened. People cared. About what? Individual stocks.
We're seeing lots of companies snapping up their peers, and the market is applauding.
Plus, we preview Wednesday's Trump-Erdogan meeting and check out AbbVie's huge debt offering as well as the new Abode-Microsoft connection.
There are plenty of stocks that have been thrown away for several weeks because of a belief that the Fed and a trade deal will avoid a recession.
The nation enters an electoral season. The drug companies for the most part, have no friends on either side of the aisle.
Let's take a fresh look.
These stocks are priced for total imperfection. That's just what you want.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Right now, AbbVie is the best way to capitalize on the moment and on the future.
ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
Plus, Intel results crush expectations and Starbucks solidifies its comeback.
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
Stocks see a nice surge on the open on optimism around trade talks resuming between the U.S. and China, although negotiations will be ongoing for many months and no permanent resolution seems on the horizon. The U.S. PMI Manufacturing Index also cam...
It is good to be sitting in for Doug Kass here on The Daily Diary as we open trading in the second half of 2019. June ended on an up note as all the major indices drifted up last week to close out the month and quarter. The market did an admirable j...